| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 1.1K | 17.7% |
| Total Income | 1.1K | 17.9% |
| Expenditure | 990.58 | 17.7% |
| PBT | 152.79 | 19.0% |
| Net Profit | 117.60 | 20.9% |
| OPM | 5.62% | 0.76pp |
| NPM | 10.29% | 0.26pp |
| EPS | 4.85 | 20.9% |
Granules India Ltd. Reports Q3FY25 Financial Results: Revenue from Operations at INR 11,377 Mn., down by 2% YoY; EBITDA at INR 2,303 Mn., down by 8% YoY; PAT at INR 1,176 Mn., down by 6% YoY
24 Jan 2025 · 24 Jan 2025, 06:48 pm
Summary
Granules India Ltd., a vertically integrated pharmaceutical company, announced its financial results for the quarter ended December 31, 2024. The company reported a decline in revenue from operations, EBITDA, and PAT compared to the same period last year. The revenue share from North America increased to 77% in Q3 FY25. Finished dosages, Active Pharmaceuticals Ingredients, and Pharmaceutical Formulation Intermediates contributed 76%, 12%, and 12% of revenue from operations respectively for Q3FY25. The company's ROCE for Q3 FY 25 is at 16.4% and net debt stood at INR 8,289 Mn.
Key Highlights
- 1
Revenue from operations for Q3FY25 stood at INR 11,377 Mn., a decline of 2% YoY
- 2
EBITDA for Q3FY25 was INR 2,303 Mn., a decrease of 8% YoY
- 3
PAT for Q3FY25 was INR 1,176 Mn., a reduction of 6% YoY
- 4
Revenue share from North America increased to 77% in Q3 FY25
- 5
ROCE for Q3 FY 25 is at 16.4%
- 6
Production at the Gagillapur plant was paused for risk assessment and resumed in a staggered manner in October 2024
Management Comments
Dr Krishna Prasad Chigurupati
We continue to sustain our profitable growth in the finished dosages segment, driven by our North America business. We are enhancing quality and compliance through systemic improvements across our operations, including Gagillapur. Progress on our greenfield formulation expansion at GLS remains on track, reinforcing our capabilities and driving future growth.
Informational and educational content only. Not investment advice.